U.S. markets open in 6 hours 59 minutes
  • S&P Futures

    4,378.00
    -33.75 (-0.77%)
     
  • Dow Futures

    34,865.00
    -109.00 (-0.31%)
     
  • Nasdaq Futures

    14,851.00
    -186.75 (-1.24%)
     
  • Russell 2000 Futures

    2,221.80
    -15.70 (-0.70%)
     
  • Crude Oil

    73.05
    -0.57 (-0.77%)
     
  • Gold

    1,831.20
    -4.60 (-0.25%)
     
  • Silver

    25.57
    -0.21 (-0.82%)
     
  • EUR/USD

    1.1881
    -0.0016 (-0.13%)
     
  • 10-Yr Bond

    1.2690
    0.0000 (0.00%)
     
  • Vix

    17.70
    -0.61 (-3.33%)
     
  • GBP/USD

    1.3944
    -0.0014 (-0.10%)
     
  • USD/JPY

    109.6000
    +0.1390 (+0.13%)
     
  • BTC-USD

    39,782.82
    -302.54 (-0.75%)
     
  • CMC Crypto 200

    946.34
    +15.98 (+1.72%)
     
  • FTSE 100

    7,078.42
    +61.79 (+0.88%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

Corbus In-Licenses Two Anti-Integrin Antibodies Targeting Cancer, Fibrotic Diseases Settings

·1 min read
  • Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has announced licensing deals for two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of transforming growth factor β (TGFβ).

  • TGFβ is a multifunctional cytokine involved in many cellular processes, including cell growth and differentiation, immune responses, wound healing, and tissue repair.

  • CRB-601 is an anti- α vβ8 mAb expressed by cancer cells. Corbus plans to develop CRB-601 to treat solid tumors in combination with existing therapies, including checkpoint inhibitors.

  • CRB-602 specifically inhibits both αvβ6 and αvβ8 implicated in fibrotic diseases and cancers of epithelial cell origin.

  • Both the programs are expected to enter Phase 1 studies in 2022.

  • The Company's $125 million cash and investments on hand, as of March 31, is expected to fund operations into the first quarter of 2024.

  • Under the combined terms of the two exclusive licensing agreements, Corbus will pay $2 million upfront, make potential milestone payments of up to $206 million, and pay low single-digit royalties on sales.

  • Price Action: CRBP shares are 6.68% lower at $2.03 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.